[HTML][HTML] Peptide receptor radionuclide therapy for patients with advanced lung carcinoids
BG Naraev, RA Ramirez, AT Kendi, TR Halfdanarson - Clinical lung cancer, 2019 - Elsevier
Neuroendocrine neoplasms (NEN) are a family of malignancies of diverse origin, including
the lung, gastrointestinal tract, and pancreas. Lung NEN include well differentiated …
the lung, gastrointestinal tract, and pancreas. Lung NEN include well differentiated …
Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors
Y Menda, MS O'Dorisio, S Kao, G Khanna… - Journal of Nuclear …, 2010 - Soc Nuclear Med
The purpose of this study was to conduct a phase I trial of 90Y-DOTATOC to determine the
dose-toxicity profile in children and young adults with somatostatin receptor–positive tumors …
dose-toxicity profile in children and young adults with somatostatin receptor–positive tumors …
A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor
X He, MH Na, JS Kim, GY Lee, JY Park… - Molecular …, 2011 - ACS Publications
Targeted delivery of imaging agents and therapeutics to tumors would provide early
detection and increased therapeutic efficacy against cancer. Here we have screened a …
detection and increased therapeutic efficacy against cancer. Here we have screened a …
90Y-DOTATOC dosimetry–based personalized peptide receptor radionuclide therapy
Y Menda, MT Madsen, TM O'Dorisio… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Pretherapy PET with 86Y-DOTATOC is considered the ideal dosimetry protocol for 90Y-
DOTATOC therapy; however, its cost, limited availability, and need for infusion of amino …
DOTATOC therapy; however, its cost, limited availability, and need for infusion of amino …
Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA] octreotide
M De Jong, R Valkema, A Van Gameren… - Journal of Nuclear …, 2004 - Soc Nuclear Med
In peptide receptor radionuclide therapy (PRRT) using somatostatin analogs labeled with β-
emitters, the radiosensitive kidney is the dose-limiting organ, because of high uptake and …
emitters, the radiosensitive kidney is the dose-limiting organ, because of high uptake and …
A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy
S Zitzmann, W Mier, A Schad, R Kinscherf… - Clinical Cancer …, 2005 - AACR
Purpose: Prostate carcinomas belong to the most widespread tumors, and their number is
increasing. Imaging modalities used for diagnosis, such as ultrasound, computed …
increasing. Imaging modalities used for diagnosis, such as ultrasound, computed …
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with 90Y, 111In, or 177Lu
MW Konijnenberg, M Bijster, EP Krenning… - Journal of Nuclear …, 2004 - Soc Nuclear Med
The therapeutic effects of peptide receptor–based radionuclide therapy are extensively
being investigated in rats bearing tumors. Both the dose to the tumor and the therapy-limiting …
being investigated in rats bearing tumors. Both the dose to the tumor and the therapy-limiting …
The Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177 …
C Schuchardt, HR Kulkarni, V Prasad, C Zachert… - … , Gallium-68, and Other …, 2013 - Springer
Purpose: The objective of this study is to analyze the in vivo behavior of the 177 Lu-labeled
peptides DOTATATE, DOTANOC, and DOTATOC used for peptide receptor radionuclide …
peptides DOTATATE, DOTANOC, and DOTATOC used for peptide receptor radionuclide …
Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE
Objectives The aim of this work was to calculate the radiation absorbed dose to kidneys,
liver, spleen, pituitary gland, and neuroendocrine tumors (NETs) of patients treated with 177 …
liver, spleen, pituitary gland, and neuroendocrine tumors (NETs) of patients treated with 177 …
[HTML][HTML] Long-term Nephrotoxicity after PRRT: Myth or Reality
Rationale: The kidneys are commonly considered as the potential dose-limiting organ for
peptide receptor radionuclide therapy (PRRT), making the risk of nephrotoxicity a primary …
peptide receptor radionuclide therapy (PRRT), making the risk of nephrotoxicity a primary …